Nanox Sells Shares in $15M Direct Offering
Ticker: NNOX · Form: 6-K · Filed: Nov 24, 2025 · CIK: 1795251
Sentiment: neutral
Topics: direct-offering, equity-raise, financing
Related Tickers: NNOX
TL;DR
Nanox just sold 3.8M shares at $3.92 in a direct offering, raising ~$15M.
AI Summary
On November 23, 2025, Nano-X Imaging Ltd. (Nanox) entered into a securities purchase agreement with a single institutional investor to sell 3,826,530 ordinary shares at a price of $3.92 per share, raising approximately $15 million before fees and expenses.
Why It Matters
This direct offering provides Nano-X Imaging with additional capital, which could be used for operational expansion or further development of its imaging technology.
Risk Assessment
Risk Level: medium — Direct offerings can dilute existing shareholders and may indicate a need for immediate capital, potentially signaling financial pressure.
Key Numbers
- 3,826,530 — Shares Sold (Number of ordinary shares sold in the direct offering.)
- $3.92 — Price Per Share (The price at which each ordinary share was sold.)
- ~$15M — Gross Proceeds (Estimated total funds raised before expenses.)
Key Players & Entities
- Nano-X Imaging Ltd. (company) — Issuer of shares
- Nanox (company) — Commonly referred name for Nano-X Imaging Ltd.
- November 23, 2025 (date) — Date of the securities purchase agreement
- 3,826,530 (share_count) — Number of ordinary shares sold
- $3.92 (dollar_amount) — Purchase price per ordinary share
- $15 million (dollar_amount) — Approximate gross proceeds from the offering
FAQ
Who was the single institutional investor in the direct offering?
The filing identifies the counterparty as 'a single institutional investor' but does not name the specific entity.
What are the expected use of proceeds from this offering?
The filing does not specify the intended use of the proceeds raised from the direct offering.
What is the total number of ordinary shares outstanding after this offering?
The filing does not provide the total number of ordinary shares outstanding before or after the offering.
Are there any lock-up agreements with the institutional investor?
The provided text does not mention any lock-up agreements for the shares purchased by the institutional investor.
What are the fees and expenses associated with this offering?
The filing states the purchase price is $3.92 per share, implying approximately $15 million raised 'before fees and expenses', but does not detail the specific amounts.
Filing Stats: 904 words · 4 min read · ~3 pages · Grade level 19.3 · Accepted 2025-11-24 06:02:52
Key Financial Figures
- $3.92 — y shares”) at a purchase price of $3.92 per share, in a registered direct offer
Filing Documents
- ea0266898-6k_nano.htm (6-K) — 17KB
- ea026689801ex99-1_nano.htm (EX-99.1) — 13KB
- 0001213900-25-113802.txt ( ) — 31KB
Forward-Looking Statements
Forward-Looking Statements This Form 6-K may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this Form 6-K are forward-looking statements. Such to successfully integrate VHC IT following the acquisition as well as to improve deployment speed pace and implementation quality, the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NANO-X IMAGING LTD By: /s/ Ran Daniel Name: Ran Daniel Title: Chief Financial Officer Date: November 24, 2025 2 EXHIBIT INDEX Exhibit No. Exhibit 99.1 Press release dated November 23, 2025. 3